Review ArticlesCirculating Tumor DNA Biomarkers for Early Detection of OligometastasisRoutman, David M. MD*; Chera, Bhishamjit S. MD†; Gupta, Gaorav P. MD, PhD†Author Information From the *Department of Radiation Oncology, Mayo Clinic, Rochester, MN †Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. B.S.C holds ownership interest (including patents) in and is a consultant/ advisory board member for Naveris, Inc. G.P.G. holds ownership interest (including patents) in and is a consultant/advisory board member for Naveris, Inc. D.M.R. reports no conflicts of interest. Reprints: Gaorav P. Gupta, MD, PhD, Department of Radiation Oncology, University of North Carolina Hospitals, 101 Manning Dr, CB #7512, Chapel Hill, NC 27599. E-mail: email@example.com. The Cancer Journal: March/April 2020 - Volume 26 - Issue 2 - p 116-123 doi: 10.1097/PPO.0000000000000437 Buy Metrics Abstract Oligometastasis represents an intermediate disease stage between localized and widely metastatic cancer. Efficient identification of patients with oligometastasis remains a barrier for accrual on clinical trials of oligometastasis-directed therapy. Here we review the prospect of circulating tumor DNA–based monitoring to promote sensitive, specific, and cost-efficient detection of cancer recurrence during posttreatment surveillance. Thus, an impetus for the development and implementation of clinical-grade circulating tumor DNA assays should be for the positive impact they will have on clinical investigations of oligometastasis-directed therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.